FDA grants emergency use of Novavax COVID-19 vaccine, adjuvanted in patients 12 years and older

Article

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization of Novavax COVID-19 Vaccine, adjuvanted in patients 12 years and older with COVID-19, according to an announcement from the FDA.1

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen.2

The Novavax COVID-19 vaccine, adjuvanted is comprised of the SARS-CoV-2 spike protein and Matrix-M adjuvant.

According to the FDA, adjuvants are integrated into vaccines to increase the immune response. In this particular vaccine, the spike protein is produced in insect cells. Moreover, the Matrix M-adjuvant includes saponin extracts from the bark of the native Chilean soapbark tree.

As with other available COVID-19 vaccines, there are some reported side effects. The most commonly reported side effects reported by Novavax vaccine recipients included redness and swelling at the injection site, pain/tenderness, fatigue, muscle pain, joint pain, headache, nausea/vomiting, and fever.

The vaccine is administered as a 2-dose primary series, with those 2 doses given 3 weeks apart.

For more information on the Novavax COVID-19 vaccine, adjuvanted, visit www.FDA.gov.

References:

1. Novavax covid-19 vaccine, adjuvanted. FDA. August 19, 2022. Accessed August 22, 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted

2. COVID-19 Vaccination. Centers for Disease Control and Prevention. August 19, 2022. Accessed August 22, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Jihong Liu, ScD, explains how to improve perinatal outcomes in COVID patients | Image Credit: sc.edu.
Jihong Liu, ScD, highlights adverse perinatal outcomes linked to the COVID pandemic | Image Credit: sc.edu.
Ryan Haumschild, PharmD
COVID-19 Therapy Roundtable: Focusing on inpatient care
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Related Content
© 2025 MJH Life Sciences

All rights reserved.